Spectranetics enrolls first patient in above-the-knee arterial-blockage study

By Elaine Rigoli

Tampa, Fla., July 20 - Spectranetics Corp. said it enrolled the first patient in a trial that will enroll 85 patients at up to 15 sites to provide clinical data on the reduction of blockage in above-the-knee arteries following use of Spectranetics' Turbo-Booster product.

The company said the first patient is a 72-year-old female suffering from severe circulation problems. The artery treated was 6 millimeters in diameter and was 85% blocked prior to the procedure.

Following multiple passes with the Turbo-Booster device, the stenosis was reduced to 25%.

The results of the procedure were sufficient for a stand-alone case result that did not require further adjunctive treatment with other devices.

"The Spectranetics Turbo-Booster opens the realm of vessel treatment to include vessels much larger than those treated by existing laser technology, and has the potential to treat every vessel from the groin to the toes using the laser," said David Allie, a trial investigator at Southwest Medical Center in Lafayette, La., in a statement.

Based in Colorado Springs, Colo., Spectranetics develops single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.